Adaptive Biotechnologies (ADPT) Cash from Financing Activities (2018 - 2026)

Adaptive Biotechnologies (ADPT) has 9 years of Cash from Financing Activities data on file, last reported at $7.5 million in Q1 2026.

• Quarterly Cash from Financing Activities rose 37.59% year-over-year to $7.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.5 million (up 474.58% YoY) and the FY2025 annual result came in at $30.4 million, up 12515.35% from the prior year.
• Cash from Financing Activities slipped to $7.5 million in Q1 2026 per ADPT's latest filing, from $21.7 million in the prior quarter.
• The five-year high for Cash from Financing Activities was $125.5 million in Q3 2022, with the low at $6000.0 in Q4 2022.
• Average Cash from Financing Activities over 5 years is $10.2 million, with a median of $1.5 million recorded in 2023.
• Year-over-year, Cash from Financing Activities slumped 99.99% in 2023 and surged 16953.54% in 2025.
• Adaptive Biotechnologies' Cash from Financing Activities stood at $6000.0 in 2022, then surged by 1350.0% to $87000.0 in 2023, then soared by 45.98% to $127000.0 in 2024, then surged by 16953.54% to $21.7 million in 2025, then slumped by 65.37% to $7.5 million in 2026.
• Business Quant data shows ADPT's Cash from Financing Activities at $7.5 million in Q1 2026, $21.7 million in Q4 2025, and $1.7 million in Q3 2025.